You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Mallinckrodt
AstraZeneca
McKinsey
Harvard Business School

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

PANCURONIUM BROMIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Pancuronium Bromide patents expire, and what generic alternatives are available?

Pancuronium Bromide is a drug marketed by Dr Reddys, Elkins Sinn, Hospira, and Igi Labs Inc. and is included in eleven NDAs.

The generic ingredient in PANCURONIUM BROMIDE is pancuronium bromide. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pancuronium bromide profile page.

US ANDA Litigation and Generic Entry Outlook for Pancuronium Bromide

A generic version of PANCURONIUM BROMIDE was approved as pancuronium bromide by HOSPIRA on January 19th, 1989.

  Start Trial

Summary for PANCURONIUM BROMIDE
Drug patent expirations by year for PANCURONIUM BROMIDE
Pharmacology for PANCURONIUM BROMIDE
Medical Subject Heading (MeSH) Categories for PANCURONIUM BROMIDE

US Patents and Regulatory Information for PANCURONIUM BROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys PANCURONIUM BROMIDE pancuronium bromide INJECTABLE;INJECTION 072759-001 Jul 31, 1990 AP RX No Yes   Start Trial   Start Trial   Start Trial
Hospira PANCURONIUM BROMIDE pancuronium bromide INJECTABLE;INJECTION 072321-001 Jan 19, 1989 DISCN No No   Start Trial   Start Trial   Start Trial
Elkins Sinn PANCURONIUM BROMIDE pancuronium bromide INJECTABLE;INJECTION 072059-001 Mar 23, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
Igi Labs Inc PANCURONIUM BROMIDE pancuronium bromide INJECTABLE;INJECTION 072210-001 Mar 31, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Johnson and Johnson
Colorcon
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.